Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 9/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18706186 | 0.85 | SMYD3 (1.00) | SMYD3HPGDALDH1A1 | |
| SCHEMBL18706127 | 0.84 | SMYD3 (0.56) | SMYD3GPR119HPGD | |
| SCHEMBL18705714 | 0.81 | SMYD3 (0.66) | SMYD3HPGD | |
| SCHEMBL23015108 | 0.81 | ALDH1A1 (0.53) | SMYD3GPR119HPGDGBA1ALDH1A1 | |
| SCHEMBL29636833 | 0.81 | ALDH1A1 (0.53) | SMYD3GPR119HPGDGBA1ALDH1A1 | |
| SCHEMBL18706188 | 0.81 | SMYD3 (0.60) | SMYD3HPGDALDH1A1MAPT | |
| SCHEMBL18706159 | 0.80 | SMYD3 (0.72) | SMYD3KMT2AHPGDALDH1A1MAPT | |
| SCHEMBL18705905 | 0.80 | SMYD3 (0.64) | SMYD3HPGDALDH1A1MAPT | |
| SCHEMBL20467457 | 0.79 | ALDH1A1 (0.71) | SMYD3MEN1KMT2AHPGDPOLB | |
| SCHEMBL20768985 | 0.79 | SMYD3 (0.70) | SMYD3MEN1KMT2AGPR119HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | SMYD3 1/4885MEN1 1006/4885KMT2A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.